Evidence map›Paper›PMID 30374891›Full record

ArticlePsychopharmacology2019

Resveratrol exerts a protective effect in chronic unpredictable mild stress-induced depressive-like behavior: involvement of the AKT/GSK3β signaling pathway in hippocampus.

Jun Shen, Chujie Qu, Linling Xu, Huimin Sun, Junjian Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Therapeutic potential ofIn silico pharmacology · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jun ShenDepartment of Neurology, Zhongnan Hospital, Wuhan University, No.169, Donghu Road, Wuhan, 430071, Hubei, China.
Chujie QuDepartment of Neurology, Zhongnan Hospital, Wuhan University, No.169, Donghu Road, Wuhan, 430071, Hubei, China.
Linling XuDepartment of Neurology, Zhongnan Hospital, Wuhan University, No.169, Donghu Road, Wuhan, 430071, Hubei, China.
Huimin SunDepartment of Neurology, Zhongnan Hospital, Wuhan University, No.169, Donghu Road, Wuhan, 430071, Hubei, China.
Junjian ZhangDepartment of Neurology, Zhongnan Hospital, Wuhan University, No.169, Donghu Road, Wuhan, 430071, Hubei, China. wdsjkx@163.com.
Zhongnan Hospital of Wuhan University · CNWuhan University · CN

Funding

National Natural Science Foundation of China 81371196
6 · The paper itself

Abstract

backgroundChronic unpredictable mild stress (CUMS) is an important contributing factor for depression with inflammatory response alteration, neuron apoptosis, and decreased neurogenesis. Previous study reported that the administration of resveratrol alleviated depression by normalizing the increased proinflammatory cytokine levels and inhibiting apoptosis in the hippocampus. However, the upstream signaling pathway that regulates cytokines and apoptosis in the antidepressant effect of resveratrol remains unclear.

objectiveThe objective of this study is to investigate the possible mechanism of the effect of resveratrol on depression.

methodsMale Sprague Dawley rats were exposed to CUMS for four consecutive weeks to elicit depressive-like behavior. The rats in the drug treatment groups were injected with resveratrol (40 or 80 mg/kg/day) and fluoxetine (10 mg/kg/day) intraperitoneally for 4 weeks. Rats in two additional groups were administered LY294002 by bilateral stereotaxic microinjection into the lateral ventricle before resveratrol administration. Behavioral tests, including sucrose preference test, forced swim test, and open field test, were used after 4 weeks of a CUMS procedure to appraise depressive-like behavior. Then, the proinflammatory cytokines (TNF-α, IL-6, and IL-1β) in the hippocampus and prefrontal cortex (PFC) tissues of rats were measured. Apoptosis-related molecules such as Bax and Bcl-2 mRNA levels in the hippocampus were analyzed. Furthermore, p-Akt/Akt and p-GSK3β/GSK3β protein expression in the hippocampus were also measured.

resultsThe results show that rats were subjected to CUMS procedure exhibited depressive-like behavior, increased TNF-α, IL-6, and IL-1β levels in hippocampus and PFC, alteration of Bax and Bcl-2 mRNA levels in hippocampus, decreased p-Akt/Akt and p-GSK3β/GSK3β protein expression in hippocampus, and an increased apoptotic cell percentage in the hippocampal CA1 region. However, resveratrol (40 or 80 mg/kg) treatment reversed these behavioral and molecular changes in CUMS rats. The positive control drug fluoxetine showed a similar effect as the resveratrol treatment. When rats were injected with LY294002 before resveratrol treatment, the antidepressant effect of resveratrol was significantly attenuated, TNF-α, IL-6 and IL-1β levels in hippocampus and PFC increased again, Bax mRNA levels increased and Bcl-2 mRNA levels decreased in hippocampus, and Akt/GSK3β protein expression in hippocampus decreased.

conclusionsThe findings in the present study suggest that the antidepressant effect of resveratrol treatment may act through activation of the Akt/GSK3β signaling pathway and then regulation of proinflammatory cytokine expression and alteration of apoptosis.

Indexed as

AnimalsAntidepressive AgentsAntioxidantsBehavior, AnimalCytokinesDepressionFluoxetineGlycogen Synthase Kinase 3 betaHippocampusInterleukin-1betaInterleukin-6MalePrefrontal CortexProto-Oncogene Proteins c-aktRatsRats, Sprague-DawleyAntidepressive AgentsAntioxidantsCytokinesFluoxetineGlycogen Synthase Kinase 3 betaIl6 protein, ratInterleukin-1betaInterleukin-6Proto-Oncogene Proteins c-aktResveratrolTumor Necrosis Factor-alphaApoptosisChronic unpredictable mild stressProinflammatory cytokinesResveratrol

Identifiers

PMID30374891
OpenAlexW2899180316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.